title: Integrin antagonists for transplant immunosuppression: panacea or peril?
authors.forename: William H
authors.initials: WH
authors.lastname: Kitchens
authors.forename: Christian P
authors.initials: CP
authors.lastname: Larsen
authors.forename: Mandy L
authors.initials: ML
authors.lastname: Ford
mesh_terms: D000069594:Abatacept; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D018796:Immunoconjugates / Q000276:immunology; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000276:immunology; D039041:Integrin alpha4beta1 / Q000037:antagonists & inhibitors* / Q000276:immunology; D016169:Lymphocyte Function-Associated Antigen-1 / Q000276:immunology*; D051379:Mice; D023421:Models, Animal; D000069442:Natalizumab; D016377:Organ Transplantation; D014181:Transplantation Immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D039041:Integrin alpha4beta1; D016169:Lymphocyte Function-Associated Antigen-1; D000069442:Natalizumab; D000069594:Abatacept; C472181:efalizumab